The COVID-19 pandemic has devastated individuals, families, and institutions throughout the world. Despite the breakneck speed of vaccine development, the human population remains at risk of further devastation. The decision to not become vaccinated, the protracted rollout of available vaccine, vaccine failure, mutational forms of the SARS virus, which may exhibit mounting resistance to our molecular strike at only one form of the viral family, and the rapid ability of the virus(es) to hitch a ride on our global transportation systems, means that we are will likely continue to confront an invisible, yet devastating foe. The enemy targets one of our human physiology's most important and vulnerable life-preserving body tissues, our broncho-alveolar gas exchange apparatus. Notwithstanding the fear and the fury of this microbe's potential to raise existential questions across the entire spectrum of human endeavor, the application of an early treatment intervention initiative may represent a crucial tool in our defensive strategy. This strategy is driven by evidence-based medical practice principles, those not likely to become antiquated, given the molecular diversity and mutational evolution of this very clever "world traveler".
Keywords: Alveoli; Bronchiole; Budesonide; COVID-19; Dexamethasone; Expectorate; Gas exchange; Inflammation; L-albuterol; Methotrexate; Mucus clearance; Oxygen saturation; Postural percussion; Pulmonary hygiene; Pulse oximetry; Respiratory muscle training; SARS-CoV-2; Vibratory sonication; Vitamin D.
Copyright © 2021. Published by Elsevier B.V.